Share

April 2022; 12 (2) Case

Probable Cerebral Amyloid Angiopathy–Related Inflammation Associated With Sitravatinib

A Case Report

Christopher Ray, Kalen Dionne
First published March 1, 2022, DOI: https://doi.org/10.1212/CPJ.0000000000001162
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
162

Share

Article Information

vol. 12 no. 2 e4-e6
DOI: 
https://doi.org/10.1212/CPJ.0000000000001162
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received October 12, 2021
  • Accepted February 2, 2022
  • First Published March 1, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Christopher Ray, MD and
    2. Kalen Dionne, MD, PhD
  1. Christopher Ray, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Spouse's support: (1) NIH NIDDK, 1L40DK126092-01, Loan Repayment Award Recipient, 2 (2) NIH NIDA, T32 DA007261, T32 Trainee, 2 (3) NIH NCATS, KL2TR002346, KL2 Career Development Scholar, 2

    Research Support, Academic Entities:

    1. Spouse's support: (1) Washington University in St. Louis Diabetes Research Center (2) Washington University in St. Louis and BJC Healthcare Innovation Lab

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kalen Dionne, MD, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH NCI, U54 CA199092-05S1, co-investigator, 2019-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology, Washington University School of Medicine.
  1. Correspondence
    Dr. Ray c.ray{at}wustl.edu

Article usage

Article usage: March 2022 to November 2023

AbstractFullPdfSource
Mar 2022900066Highwire
Apr 20227135922Highwire
May 20223482610Highwire
Jun 20221411112Highwire
Jul 2022137512Highwire
Aug 20228426Highwire
Sep 20229143Highwire
Oct 20226816Highwire
Nov 202210010Highwire
Dec 20226022Highwire
Jan 20237362Highwire
Feb 20236553Highwire
Mar 20234453Highwire
Apr 20234011Highwire
May 20234550Highwire
Jun 20234637Highwire
Jul 20232940Highwire
Aug 20232963Highwire
Sep 20233641Highwire
Oct 20231841Highwire
Nov 20234612Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me